23andMe was once worth $6 billion and is now a penny stock. Layoffs, data breaches, and mass resignations plagued the genomics giant. How did it all unfold?
Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development, backed by strong research and government support.